A Community Collaboration Between IU Health and St. Vincent
Current Studies & Research
The interFACE Lab

The interFACE Lab The Interactive and Functional Assessment of Communication and Emotion (InterFACE) Center is a natural observation laboratory designed to research emotional and behavioral deficits in people with neurological,… Read More

TrackTBI

TrackTBI Investigator: Richard Rodgers, MD TRACK-TBI:  The multicenter Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study aims to improve success of clinical trial design through the collection and analysis of… Read More

Training to Reconnect with emotional awareness therapy

Training to Reconnect with emotional awareness therapy (TREAT) Investigators: Dawn Neumann, Flora Hammond The purpose of this study is to teach participants with traumatic brain injury to develop better emotional… Read More

Avanir Study

Avanir Study Sheryl Katta-Charles MD, Principal Investigator A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability or AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for… Read More

Monitoring Safety and Training in Patients with Spinal Cord Injuries

Long-Term, Prospective, Non-Interventional Study Monitoring Safety and Training in Patients with Spinal Cord Injuries and Their Trained Companions Recently Initiated with the ReWalk™ Personal Device. Flora Hammond, MD (PI), funded… Read More

SEE ALL RESEARCH
BACK
Evaluation of Memory Remediation after TBI with Donepezil August 13th, 2018

Evaluation of Memory Remediation after TBI with Donepezil (MEMRI-TBI-D Study)

Flora Hammond, MD, Principal Investigator

This study is a four-site, randomized, parallel design, double-blind, placebo-controlled, 10-week trial that will evaluate the effect of donepezil on treatment for functionally important verbal memory problems among 160 individuals (age 18-60 years) who sustained a complicated mild, moderate, or severe non-penetrating TBI six to 36 months prior to study participation. The study also will acquire data that inform on the effects of donepezil on other aspects of cognition (i.e., attention, processing speed, executive function), neuropsychiatric symptoms, community participation, and quality of life in this population as well as on caregiver burden.

Contact: Becky Runkel

Email: becky.runkel@rhin.com

Phone: 317-329-2217